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The available data on bone fractures in hemodialysis (HD)
patients are limited to results of a few studies of subgroups
of patients in the United States. This study describes the
prevalence of hip fractures and the incidence and risk factors
associated with hip and other fractures in representative
groups of HD facilities (n¼ 320) and patients (n¼ 12 782)
from the 12 countries in the second phase of the Dialysis
Outcomes and Practice Patterns Study (2002–2004). Among
prevalent patients, 2.6% had a prior hip fracture. The
incidence of fractures was 8.9 per 1000 patient years for new
hip fractures and 25.6 per 1000 for any new fracture. Older
age (relative risk (RR)HIP¼ 1.91, RRANY¼ 1.33, Po0.0001),
female sex (RRHIP¼ 1.41, P¼ 0.02; RRANY¼ 1.59, Po0.0001),
prior kidney transplant (RRHIP¼ 2.35, P¼ 0.04; RRANY¼ 1.76,
P¼ 0.007), and low serum albumin (RRHIP¼ 1.85,
RRANY¼ 1.45, per 1 g/dl lower, Po0.0001) were predictive of
new fractures. Elevated risk of new hip fracture was observed
for selective serotonin reuptake inhibitors and combination
narcotic medications (RR¼ 1.63, RR¼ 1.74, respectively,
Po0.05). Several medications were associated with risk of
any new fracture: narcotic pain medications (RR¼ 1.67,
P¼ 0.02), benzodiazepines (RR¼ 1.31, P¼ 0.03), adrenal
cortical steroids (RR¼ 1.40, Po0.05), and combination
narcotic medications (RR¼ 1.72, P¼ 0.001). Parathyroid
hormone (PTH) levels 4900 pg/ml were associated with an
elevated risk of any new fracture (RR¼ 1.72, Po0.05) versus
PTH 150–300. The results suggest that greater selectivity in
prescribing several classes of psychoactive drugs and more
efficient treatment of secondary hyperparathyroidism may
help reduce the burden of fractures in HD patients.
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The available data on risk factors for hip and other bone
fractures in hemodialysis (HD) patients remains restricted
to a few studies on selected subgroups of patients in the
United States (US).1–4 We took advantage of the prospective
gathering of data on this topic in the second phase of the
Dialysis Outcomes and Practice Patterns Study (DOPPS II)
to investigate this substantial cause of morbidity and
mortality in HD patients across 12 countries. We hypo-
thesized that both severe hyperparathyroidism and various
drugs, especially psychoactive medications known to
cause falls and fractures in elderly non-uremics, would be
independent risk factors for bone fractures in HD patients.
RESULTS
Across all 12 countries participating in the DOPPS II, 2.6% of
the prevalent cross-section of patients had a prior hip
fracture, with less than a threefold difference between the
highest (3.9% in France) and the lowest (1.4% in Germany)
country prevalence of history of prior hip fracture (Table 1).
In the US, 2.7% of patients had a prior hip fracture. The
overall unadjusted incidence of new hip fracture events was
8.9 per 1000 patient years at risk (95% confidence interval
(CI)¼ 8.4–9.4 per 1000 patient years), whereas the incidence
of new fracture events of any type was 25.6 per 1000 patient
years (95% CI¼ 24.4–27.0 per 1000 patient years). The
incidence of these events in the US was modestly higher than
the incidence overall, with 9.9 hip fractures per 1000 patient
years (95% CI¼ 8.9–11.1 per 1000 patient years) and 24.8
fractures of any type per 1000 patient years (95%
CI¼ 22.5–27.5 per 1000 patient years). Outside the US, the
incidence of these events was 8.6 hip fractures per 1000
patient years (95% CI¼ 8.0–9.2 per 1000 patient years) and
25.9 fractures of any type per 1000 patient years (95%
CI¼ 24.4–27.4 per 1000 patient years).
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In multivariable logistic regression models, a variety of
baseline patient characteristics and treatment parameters
were significantly associated with having a prior hip fracture
(Table 2). After controlling for an array of demographic,
comorbidity, and laboratory factors, Spain and Sweden had
significantly lower adjusted odds ratios (AORs) of a patient
having a prior hip fracture (AOR¼ 0.41 and 0.45, respec-
tively, 0.05oPo0.01) compared with the US; no countries
exhibited a significantly greater likelihood of a patient having
a prior hip fracture than the US (data not shown). Among
the demographic factors associated with a higher likelihood
of having a prior hip fracture were greater age (AOR¼ 1.17
per 10 years older, P¼ 0.02), female sex (AOR¼ 1.56,
P¼ 0.002), non-black versus black race (AOR¼ 1.96,
P¼ 0.02), lower body mass index (BMI) (1.05 per 1 unit
lower, P¼ 0.004), and a greater number of years on dialysis
(AOR¼ 1.07 per 1 year longer, Po0.0001). Patients who
needed assistance to walk or who resided in a nursing home
also had a higher likelihood of having a prior hip fracture
(AOR¼ 3.05, Po0.0001 and AOR¼ 1.75, P¼ 0.02, respec-
tively). Examining categories of age by sex revealed that the
adjusted odds of prior hip fracture did not differ significantly
in older male subjects compared with male subject aged
18–54. However, among female subjects, the adjusted odds of
having a prior hip fracture were progressively greater with
age, becoming significantly greater for females aged 65–74
and X75 (AOR¼ 1.89 and 2.69, respectively, Po0.05)
compared with females aged 18–54.
In general, comorbid conditions were not found to
correlate with prior hip fracture, although the occurrence
of certain prior events such as prior parathyroidectomy
(AOR¼ 1.70, P¼ 0.02) and the presence of specific condi-
tions such as carpal tunnel syndrome or b2-microglobulin
disorder (AOR¼ 1.79, P¼ 0.007) were associated with higher
odds of prior hip fracture. With respect to serum phosphorus
levels, associations with prior hip fracture were only observed
among patients with a phosphorus level of X5.5 mg/dl
(AOR¼ 0.67 versus 3.5–4.49 mg/dl, P¼ 0.03). Similarly, with
serum calcium, the overall trend was not significant; however,
patients with calcium of X10.2 mg/dl had greater odds of
having had a prior hip fracture (AOR¼ 1.57 versus
8.4–9.5 mg/dl, P¼ 0.02). Significantly greater odds of prior
hip fracture were observed among patients with a serum
albumin p3.3 g/dl (AOR¼ 1.65 versus 44.0 g/dl, P¼ 0.05).
As a continuous predictor, lower albumin tended to be
associated with higher odds of hip fracture, although the
results only approached statistical significance (AOR¼ 1.23
per 1 g/dl lower, P¼ 0.12). Compelling baseline factors that
were not associated with prior hip fracture were PTH and
bicarbonate levels, and prior kidney transplant.
Throughout follow-up in all 12 countries, there were 174
new hip fracture events and 489 reported fractures of any
type. Using this information along with the corresponding
hospital admission or event occurrence dates, we analyzed the
time from enrollment to first reported occurrence of either
hip fracture or fracture of any type. Eleven percent of new hip
fracture events occurred among patients with a reported
prior hip fracture before enrollment. Model results were
substantially equivalent regardless of whether the prospective
analyses controlled for a patient’s history of hip fracture or
were restricted to patients without a prior hip fracture. The
results presented herein are those from prospective analyses
controlling for patient’s history of hip fracture. Not
surprisingly, prior hip fracture was highly correlated with
greater risk of a new hip fracture (RR¼ 4.52, Po0.0001) and
fracture of any type (RR¼ 3.17, Po0.001) (Table 3).
Older age (RRHIP¼ 1.91, Po0.0001; RRANY¼ 1.33,
Po0.0001) and female sex (RRHIP¼ 1.41, P¼ 0.02;
RRANY¼ 1.59, Po0.0001) were highly predictive of both
new hip fractures and fractures of any type. Analyzing age by
sex confirmed these findings and also demonstrated that the
RR of new fractures with older age was especially pronounced
Table 1 | Prevalence of prior hip fracture and incidence of new hip fracture and fracture of any type
Hip fracture
Country
Prevalencea of history of
hip fracture (%)
Incidenceb of new hip
fracture (95% CI)
Incidenceb of any new
fracture (95% CI)
Australia–New Zealand 2.5 10.2 (8.1, 12.9) 30.6 (25.0, 37.6)
Belgium 3.7 15.7 (12.7, 19.3) 40.8 (33.8, 49.3)
Canada 3.8 8.6 (7.0, 10.7) 29.6 (24.5, 35.6)
France 3.9 11.4 (9.0, 14.4) 23.1 (18.7, 28.5)
Germany 1.4 7.2 (5.8, 9.1) 20.6 (16.8, 25.2)
Italy 3.1 8.1 (6.5, 10.1) 21.0 (17.2, 25.8)
Japan 2.2 4.9 (4.3, 5.7) 23.3 (20.6, 26.3)
Spain 1.6 6.7 (5.4, 8.2) 14.2 (11.6, 17.4)
Sweden 2.4 15.1 (12.3, 18.7) 42.3 (35.0, 51.1)
UK 2.3 5.1 (4.0, 6.5) 20.4 (16.5, 25.3)
USc 2.7 9.9 (8.9, 11.1) 24.8 (22.5, 27.5)
All DOPPSd 2.6 8.9 (8.4, 9.4) 25.6 (24.4, 27.0)
CI, confidence interval; DOPPS, Dialysis Outcomes and Practice Patterns Study.
aAmong prevalent cross-section of patients (n=9089).
bIncidence=per 1000 patient years (patyrs) at risk, among all patients (n=12 782).
cUS-DOPPS: 44 hip fractures (4328 patyrs at risk), 108 any fractures (4266 patyrs at risk).
dAll DOPPS: 174 hip fractures (18 664 patyrs at risk), 489 any fractures (18 345 patyrs at risk).
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among females (Table 3). Patients with a prior kidney
transplant also exhibited a higher RR of both new hip
fractures (RR¼ 2.35, P¼ 0.04) and fractures of any type
(RR¼ 1.76, P¼ 0.007). Lower serum albumin as a continu-
ous measure correlated with higher RR of both new hip
fractures (RR¼ 1.85 per 1 g/dl lower, Po0.0001) and frac-
tures of any type (RR¼ 1.45 per 1 g/dl lower, Po0.0001).
Confirmation of this trend for serum albumin was clearly
demonstrated upon analyzing approximate quintiles of
albumin levels, with the greatest risk occurring among
patients with albuminp3.3 g/dl (RRHIP¼ 3.59, RRANY¼
1.91, both Pp0.00001) versus albumin 44.0 g/dl (Table 3).
Factors significantly associated with RR of a new hip fracture
that were not predictive of fractures of any type included
congestive heart failure (RR¼ 1.46, P¼ 0.04) and lung
disease (RR¼ 0.59, P¼ 0.04). Conversely, factors associated
with RR of a new fracture of any type, but not of a new hip
fracture, included non-black (RR¼ 1.79, P¼ 0.01) versus
black race, lower BMI (RR¼ 1.02 per 1 unit, P¼ 0.03), several
categories of years on HD, PTH 4 900 (RR¼ 1.72, P¼ 0.03)
versus 150–300 pg/ml, and neurologic disorders other than
dementia (RR¼ 0.67, P¼ 0.02) (Table 3, Figure 2).
In prospective Cox models that adjusted only for age, sex,
country, and one medication at a time (univariate models), a
significantly higher RR of both types of new fracture events
was observed for several classes of medications, including
adrenal cortical steroids (e.g., prednisone, hydrocortisone,
and methylprednisolone), any type of antidepressant (AD)
medication (including general AD medications, miscella-
neous AD medications, selective serotonin reuptake inhibi-
tors (SSRIs), tricyclics, and monoamine oxidase inhibitors),
the SSRI class of AD medications in particular (e.g.,
sertraline, citalopram, paroxetine, and fluoxetine), combina-
tion narcotic medications (e.g., acetaminophen–codeine,
acetaminophen–hydrocodone, and acetaminophen–oxy-
codone), and narcotic pain medications (e.g., oxycodone,
morphine, and codeine). Furthermore, in these univariate
models benzodiazepines (e.g., lorazepam, temazepam, and
diazepam), the nonspecific class of miscellaneous anti-
convulsants (e.g., gabapentin, carbamazepine, and lamotri-
gine), and multivitamins (nonspecific over-the-counter
multivitamin preparations), but not statins or beta-blocking
Table 2 | Associations between history of hip fracture and
baseline patient characteristics
Characteristic (n/N pts)
Adjusted odds ratio of
history of hip fracture
(95% CI)
Age, per 10 years older (N=9089) 1.17* (1.03, 1.32)
Female, versus male (3871/9089) 1.56** (1.18, 2.07)
Male, 18–54 (1575/9089) 1.00 (Ref.)
Male, 55–64 (1152/9089) 1.12 (0.59, 2.14)
Male, 65–74 (1381/9089) 1.34 (0.78, 2.37)
Male, X75 (1110/9089) 0.87 (0.44, 1.72)
Female, 18–54 (1022/9089) 0.94 (0.53, 1.67)
Female, 55–64 (850/9089) 1.32 (0.70, 2.51)
Female, 65–74 (1082/9089) 1.89* (1.14, 3.15)
Female, X75 (917/9089) 2.69** (1.52, 4.78)
Non-black race, versus black race
(8238/9089)
1.96* (1.12, 3.45)
BMI, per 1 unit lower 1.05** (1.02, 1.09)
p21.6 (2823/8554) 1.39 (0.99, 1.96)
21.7–25.8 (2861/8554) 1.00 (Ref.)
425.8 (2870/8554) 0.75 (0.52, 1.08)
Years on dialysis, per 1 year longer 1.07*** (1.04, 1.09)
p0.5 yrs (1052/9018) 1.00 (Ref.)
0.6–0.99 yrs (874/9018) 1.92 (0.78, 4.75)
1.0–1.99 yrs (1522/9018) 2.86* (1.44, 5.69)
2.0–2.99 yrs (1162/9018) 2.51* (1.17, 5.37)
3.0–3.99 yrs (917/9018) 3.20** (1.51, 6.76)
X4.0 yrs (3491/9018) 3.85*** (1.95, 7.59)
Prior transplant, yes versus no
(626/9089)
1.52 (0.84, 2.75)
Prior parathyroidectomy, yes versus
no (610/8978)
1.70* (1.06, 2.74)
Needs assistance to walk, yes versus
no (2131/8798)
3.05*** (2.20, 4.24)
Resides in nursing home, yes versus
no (459/8819)
1.75* (1.10, 2.77)
Phosphorus, per 1 mg/dl lower 1.06 (0.96, 1.17)
o3.5 (847/8580) 1.10 (0.72, 1.67)
3.50–4.49 (1613/8580) 1.00 (Ref.)
4.50–5.49 (2062/8580) 0.71 (0.48, 1.05)
X5.50 (4058/8580) 0.67* (0.47, 0.96)
Calcium, per 1 mg/dl higher 1.17 (0.99, 1.39)
o8.4 (636/7828) 1.02 (0.53, 1.96)
8.4–9.5 (3125/7828) 1.00 (Ref.)
9.6–10.1 (2275/7828) 1.10 (0.75, 1.60)
X10.2 (1792/7828) 1.57* (1.07, 2.31)
Albumin, per 1 g/dl lower 1.23 (0.94, 1.64)
p3.30 (1387/8206) 1.65* (41.00, 2.72)
3.31–3.60 (1956/8206) 1.46 (0.91, 2.35)
3.61–3.80 (1317/8206) 1.22 (0.72, 2.07)
3.81–4.00 (1703/8206) 1.33 (0.79, 2.24)
44.00 (1843/8206) 1.00 (Ref.)
PTH, per 200 pg/ml higher (N=6225) 1.00 (0.92, 1.09)
Bicarbonate, per 1 mEq/l higher
(N=5757)
1.03 (0.99, 1.08)
Comorbid conditions, yes versus no
Carpal tunnel syndrome or b2-
microglobulin disorder (929/9005)
1.79** (1.17, 2.74)
Coronary artery disease (4127/9089) 0.89 (0.65, 1.22)
Cancer, other than skin (1055/8950) 1.16 (0.78, 1.74)
Other cardiovascular disease
(3271/9023)
1.23 (0.91, 1.65)
Cerebrovascular disease (1544/9006) 1.08 (0.75, 1.57)
Congestive heart failure (2632/9002) 1.12 (0.83, 1.49)
Diabetes mellitus (3104/9012) 1.09 (0.79, 1.52)
Gastrointestinal bleeding (524/8985) 1.29 (0.79, 2.10)
Hypertension (7043/8993) 1.10 (0.77, 1.58)
Lung disease (969/9012) 1.23 (0.83, 1.83)
Dementia (266/8997) 1.08 (0.60, 1.94)
Table 2 | Continued
Characteristic (n/N pts)
Adjusted odds ratio of
history of hip fracture
(95% CI)
Other neurologic disorder (869/9010) 1.37 (0.93, 2.03)
Psychiatric disorder (1719/9013) 1.31 (0.97, 1.75)
Peripheral vascular disease (2362/9014) 1.19 (0.86, 1.64)
Recurrent cellulitis (726/8979) 0.90 (0.55, 1.46)
CI, confidence interval; BMI, body mass index; PTH, parathyroid hormone; yrs, years.
*0.01oPp0.05; **0.0001oPp0.01; *** Pp0.0001.
DOPPS II data (2002–2004) among prevalent cross-section of patients; n/N=number
of patients with given characteristic/number of patients for whom data on that
characteristic were available. Logistic models controlled for effects of facility
clustering and adjusted for all factors listed in Table 2 – continuous and categorical
variables run in separate models.
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agents, were associated with a higher RR of new fractures of
any type but not hip fracture events (Table 4).
In prospective Cox models that also adjusted for demo-
graphics, comorbidity, and laboratory measures (multivariable
models), the significantly elevated association remained
between RR of new hip fracture and both SSRI AD medica-
tions and combination narcotic medications (RR¼ 1.63 and
RR¼ 1.74, respectively; both Po0.05). Moreover, the following
classes of medications remained significantly associated with
RR of any type of fracture in the multivariable models:
adrenal cortical steroids (RR¼ 1.40, Po0.05), benzodiazepines
(RR¼ 1.31, P¼ 0.03), multivitamins (RR¼ 1.22, P¼ 0.02),
combination narcotic medications (RR¼ 1.72, P¼ 0.001), and
narcotic pain medications (RR¼ 1.67, P¼ 0.02) (Table 4).
Examination of the facility-level practice of prescribing multi-
vitamins revealed no significant associations between new
fractures and higher percentages of patients prescribed multi-
vitamins within facilities.
Table 3 | Associations between patient characteristics and RR of new hip fracture or new fracture of any type
Characteristic (n/N pts) RR of hip fracture (95% CI) RR of any fracture (95% CI)
Prior hip fracture (258/12,552) 4.52*** (2.57, 7.97) 3.17*** (2.13, 4.70)
Age, per 10 years older (N=12,782) 1.91*** (1.63, 2.25) 1.33*** (1.23, 1.45)
Female, versus male (5342/12,782) 1.41* (1.04, 1.89) 1.59*** (1.32, 1.92)
Male, 18–54 (2197/12,782) 1.00 (Ref.) 1.00 (Ref.)
Male, 55–64 (1622/12,782) 2.15* (1.01, 4.57) 1.25 (0.84, 1.85)
Male, 65–74 (1956/12,782) 2.38* (1.07, 5.26) 1.65* (1.10, 2.48)
Male, X75 (1664/12,782) 5.05*** (2.36, 10.82) 1.86** (1.24, 2.77)
Female, 18–54 (1420/12,782) 0.85 (0.30, 2.35) 1.07 (0.67, 1.69)
Female, 55–64 (1133/12,782) 1.85 (0.75, 4.59) 2.36*** (1.56, 3.54)
Female, 65–74 (1488/12,782) 4.67*** (2.22, 9.83) 2.58*** (1.79, 3.63)
Female, X75 (1301/12,782) 7.79*** (3.69, 16.43) 3.43*** (2.33, 5.06)
Non-black race, versus black race (11614/12,782) 2.02 (0.93, 4.34) 1.79* (1.14, 2.78)
BMI, per 1 unit lower 1.03 (0.99, 1.07) 1.02* (1.01, 1.04)
p21.6 (3634/11,747) 1.04 (0.72, 1.50) 1.18 (0.93, 1.49)
21.7–25.8 (3967/11,747) 1.00 (Ref.) 1.00 (Ref.)
425.8 (4146/11,747) 0.78 (0.51, 1.18) 1.04 (0.83, 1.32)
Years on dialysis, per 1 year longer 1.02 (0.99, 1.06) 1.01 (0.99, 1.03)
p0.5 yrs (4625/12,709) 1.00 (Ref.) 1.00 (Ref.)
0.6–0.99 yrs (888/12,709) 1.04 (0.57, 1.90) 1.16 (0.79, 1.65)
1.0–1.99 yrs (1548/12,709) 1.27 (0.78, 2.07) 1.36* (1.00, 1.79)
2.0–2.99 yrs (1177/12,709) 1.18 (0.69, 2.03) 1.68** (1.21, 2.27)
3.0–3.99 yrs (931/12,709) 0.90 (0.48, 1.69) 1.54* (1.09, 2.14)
X4.0 yrs (3540/12,709) 1.14 (0.74, 1.73) 1.53** (1.16, 2.04)
Prior transplant, yes versus no (693/12,782) 2.35* (1.03, 5.36) 1.76** (1.16, 2.66)
Prior parathyroidectomy, yes versus no (654/12,528) 1.19 (0.58, 2.43) 1.24 (0.86, 1.78)
Needs assistance to walk, yes versus no (3083/12,342) 1.39 (0.97, 1.99) 1.18 (0.95, 1.46)
Phosphorus, per 1 mg/dl lower 0.99 (0.89, 1.10) 1.04 (0.98, 1.11)
o3.5 (1174/11,743) 1.62 (0.94, 2.81) 1.29 (0.93, 1.77)
3.50–4.49 (2228/11,743) 1.00 (Ref.) 1.00 (Ref.)
4.50–5.49 (2828/11,743) 1.26 (0.78, 2.04) 0.98 (0.76, 1.29)
X5.50 (5513/11,743) 1.29 (0.81, 2.06) 0.98 (0.77, 1.31)
Calcium, per 1 mg/dl higher 1.00 (0.82, 1.22) 1.10 (0.97, 1.25)
o8.4 (1135/10,503) 0.93 (0.46, 1.87) 0.86 (0.58, 1.34)
8.4–9.5 (4427/10,503) 1.00 (Ref.) 1.00 (Ref.)
9.6–10.1 (2845/10,503) 0.91 (0.60, 1.36) 0.96 (0.74, 1.23)
X10.2 (2096/10,503) 1.08 (0.69, 1.68) 1.20 (0.92, 1.59)
Albumin, per 1 g/dl lower 1.85*** (1.41, 2.44) 1.45*** (1.25, 1.72)
p3.30 (2582/11,043) 3.59*** (1.77, 7.25) 1.91*** (1.39, 2.66)
3.31–3.60 (2601/11,043) 2.81** (1.39, 5.69) 1.59** (1.16, 2.21)
3.61–3.80 (1636/11,043) 3.06** (1.44, 6.54) 1.55* (1.08, 2.24)
3.81–4.00 (2042/11,043) 2.51* (1.19, 5.27) 1.29 (0.90, 1.85)
44.00 (2182/11,043) 1.00 (Ref.) 1.00 (Ref.)
PTH, per 200 pg/ml higher 0.95 (0.79, 1.14) 1.09* (1.01, 1.17)
o150 (3523/8162) 1.27 (0.78, 2.06) 1.05 (0.80, 1.38)
150–300 (2267/8162) 1.00 (Ref.) 1.00 (Ref.)
301–600 (1524/8162) 1.19 (0.63, 2.26) 1.24 (0.88, 1.76)
601–750 (295/8162) 0.33 (0.05, 2.37) 0.86 (0.41, 1.77)
751–900 (185/8162) 0.62 (0.08, 4.87) 1.03 (0.35, 3.08)
4900 (368/8162) 1.14 (0.34, 3.80) 1.72* (1.02, 2.90)
BMI, body mass index; PTH, parathyroid hormone; RR, relative risk; yrs, years.
*0.01oPp0.05; **0.0001oPp0.01; ***Pp0.0001.
DOPPS II data (2002–2004); n/N=number of patients with given characteristic/number of patients for whom data on that characteristic were available. Cox models controlled
for effects of facility clustering and adjusted for all factors listed in Table 3 – continuous and categorical variables run in separate models.
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DISCUSSION
This study has identified several new risk factors for hip and
other bone fractures in HD patients. The extensive adjust-
ment for comorbidity typical of DOPPS studies5,6 and the
consistency of the findings across 12 countries and four
continents suggest promising opportunities for the preven-
tion of bone fractures in HD patients.
A first new finding is the detection of an independent role
of drugs in the onset of fractures. Previous evidence
concerning this topic in end-stage renal disease (ESRD)
patients was limited to the well-known deleterious impact
of steroids on bone mass, probably accounting for the
substantial risk of fractures in renal transplant recipients.1 In
addition to adrenal cortical steroids, our study further
identified the use of SSRIs, benzodiazepines, narcotics, and
multivitamins as independent risk factors for both hip and
other bone fractures. Although the finding of a correlation
with multivitamins very likely is a case of confounding by
indication, the other findings, new in the ESRD population,
are in line with numerous studies demonstrating a high risk
of falling and attendant fracture in the elderly under
benzodiazepines, ADs, or narcotics.2,7–10
While previous studies of the risk of fractures among HD
patients focused almost exclusively on the determinants of
bone disease (or osteopenia), our study broadens the
perspective to potential risk factors for falling. Previous
studies in the general population documented that risk
factors for falling or a history of falling were strongly
associated with the risk of subsequent fractures, even more
strongly in some studies than the association between risk
factors for osteoporosis or actual low-bone mineral density
and the risk of subsequent fractures.11–13 Our results are in
line with a recent prospective study demonstrating a high
incidence of falls among in-center Belgian HD patients.14
Independent risk factors for falling included, among others,
the intake of an AD, older age, diabetes, and the inability to
successfully perform a simple walking test. While intake of
any AD, frequently implicated in falls and fractures among
the non-uremic elderly, was associated with a higher risk of
falling in the earlier study, the risk of fractures in the present
study was significantly associated with SSRI intake, and
tended to be so with tricyclics, although not significantly.
This difference may be due to residual confounding (despite
the adjustment for many comorbid conditions in the
DOPPS) with SSRIs being prescribed preferentially to frailer
patients. Indeed, the published evidence from elderly non-
uremics suggests that both classes of ADs (SSRIs and
tricyclics) increase the risk of falls and fractures.15,16 Alter-
natively, the much longer experience with tricyclics may
reduce the associated risk (e.g., because lower dosages are
prescribed). Overall, our findings do not contradict the
importance of the effective treatment of depression, a poor
prognostic marker in HD patients,17 but underscore that
drug treatment of depression should always carefully
integrate the potential benefits and risks of such treatment.
Other drugs such as benzodiazepines, narcotics, and
adrenal cortical steroids should also be prescribed for HD
patients only after fully considering the potential risks and
benefits associated with their intake.
Our study addressed for the first time the potential
association of the use of statins with the risk of fracture
in HD patients. A potential protective effect of statins
was suggested by the recent finding of an association of a
low-cholesterol serum level (potentially reflecting statin
Table 4 | RR of new fracture events, by patient baseline medication prescription
Univariatea model Multivariateb model
Medication Patients, N (%) RR hip fracture RR any fracture RR hip fracture RR any fracture
Adrenal cortical steroid 871 (6.9) 1.77* 1.65** 1.39 1.40*
Anticonvulsants, miscellaneous 490 (3.9) 1.37 1.54* 1.12 1.39
AD, any type 1,350 (10.7) 1.71* 1.43** 1.45 1.28
SSRI antidepressants 869 (6.9) 1.85* 1.48* 1.63* 1.31
Tricyclic antidepressants 334 (2.7) 1.54 0.95 1.20 0.85
Miscellaneous ADs 218 (1.7) 1.27 1.67 1.08 1.53
Benzodiazepines 2,171 (17.2) 1.28 1.41** 1.19 1.31*
Beta-blocking agents 3,793 (30.1) 0.92 0.94 0.85 0.90
Estrogen hormones – females only 171 (3.2) 1.84 1.64 1.72 1.47
Multivitamin preparations 6,024 (47.8) 1.04 1.25* 1.03 1.22*
Narcotic combinations 706 (5.6) 2.01** 1.94** 1.74* 1.72**
Narcotic pain medications 372 (3.0) 1.90* 1.98** 1.55 1.67*
(Anti-) Parkinson disease agents 134 (1.1) 0.90 0.75 1.03 0.89
Phenothiazine antipsychotics 151 (1.2) 1.13 1.79 1.15 1.81
Sedatives 303 (2.4) 1.53 1.40 1.32 1.25
Sedatives, miscellaneous 897 (7.1) 1.47 1.31 1.35 1.21
Statins 2,616 (20.8) 1.15 0.92 1.17 0.95
AD, antidepressants; RR, relative risk; SSRI, selective serotonin reuptake inhibitor.
*0.01oPp0.05; **Pp0.01.
DOPPS II data (2002–2004), among all patients (n=12 782); shown are results for medications prescribed to 41% of patients.
aAdjusted for one medication per model, plus age, sex, and country.
bAdjusted for one medication per model, plus age, sex, race, vintage, comorbidities, BMI, phosphorus, calcium, PTH, albumin, prior transplant, prior PTX, needing assistance to
walk, and country.
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treatment, not recorded in this study) with a lower risk of
hospitalization for fracture,18 as well as by the recent
demonstration of a beneficial impact of pravastatin on bone
turnover in uremic rats (Iwasaki-Ishizuka Y, Yamato H, and
Fukagawa M. Pravastatin ameliorates suppressed bone
formation in uremic rats with adynamic bone disease.
J Am Soc Nephrol 2004; 15: 8A). The evidence suggesting a
protective effect of statins for fractures in the general
population remains controversial. Indeed, whereas the results
of case–control studies suggest a protective effect, the post hoc
analysis of randomized controlled trials of statins prescribed
for hypercholesterolemia do not suggest a protective role.19
At any rate, our results indicating a modestly protective, yet
statistically nonsignificant association do not suggest that
statins should be prescribed to HD patients specifically with
the hope of reducing their risk of fracture. Our study did not
find any reduction of the risk of new hip or other fracture
with the intake of beta-blocking agents, in contrast to recent
data on non-uremics.20 This discrepancy likely reflects the
different pathophysiology of fractures and the variable
adjustment for comorbidity in the respective studies. Finally,
our study found a moderate but nonsignificant positive
association of the risk of bone fracture with the intake of
estrogens and significant direct association with multi-
vitamins, both very likely explained by confounding by
indication.
Another interesting finding is evidence suggesting that a
high PTH level may be an independent risk factor for bone
fractures. Stehman-Breen et al.21 did not detect such an
association in ESRD patients from the US in the Dialysis
Morbidity and Mortality Study Wave 1. Coco et al.3 observed
that a low PTH level was associated with a higher risk of hip
fracture in a cohort of some 1200 HD patients in the US.
These discrepancies may result from the smaller size or
limited adjustment for comorbidity in the previous studies,
or alternatively from the availability of only a single PTH
measurement for most patients, a limitation potentially
obscuring an association of the burden of hyperparathyroid-
ism over time with subsequent fractures. In addition, the
results of Danese et al.22 suggest that the relationship of PTH
level to fracture may be U-shaped, a suggestion that we were
unable to confirm. Our findings suggest that control of
excessive hyperparathyroidism may contribute to reducing
the incidence of bone fractures in HD patients. This
suggestion is in line with the recent post hoc analysis
demonstrating a reduction of the risk of fractures in patients
randomized to cinacalcet versus placebo4 and with a recent
analysis of data from the Dialysis Morbidity and Mortality
Study Waves 1, 3, and 4.22
Our study further confirms several risk factors for bone
fractures already identified both in the general population
and in the few prior studies on fractures in HD patients: low
BMI, female sex, older age, non-black versus black race, a
history of transplantation, length of time on HD, and a
history of previous hip fracture.1,3,21 Our study did not
identify diabetes as an independent risk factor for hip or any
fractures in HD patients. This is in agreement, for hip
fractures, with the paper of Stehman-Breen et al.21 on
Dialysis Morbidity and Mortality Study Wave 1 HD patients,
but not with that of Ball et al.,1 from the same group, on
wait-listed HD patients and transplant recipients. Similarly,
in the general population, some23,24 but not all11 studies have
identified diabetes as an independent risk factor for hip
fractures. Clearly this area requires further investigation.
In addition to identifying new risk factors and confirming
existing factors for bone fractures in HD patients, this
study introduces several descriptive correlations between
patient characteristics and prior hip fractures (Table 2).
Direct interpretation of these results admittedly is limited, yet
such retrospective associational analyses are informative as
hypothesis-generating explorations. Although testing these
hypotheses may be beyond the scope and ability of the
present investigation, we present the information to the
larger community, which may have additional supportive
data or the means to effectively test the hypotheses these data
suggest.
Finally, our results extend the available data on the
incidence of hip fractures in HD patients. Previous studies
reported a yearly incidence of about 1% among white ESRD
patients in the US and 0.3% among wait-listed dialysis
patients in the US.1,25 The results of these studies were not
generalizable as a result of the inclusion of only white
patients in one and only wait-listed patients in the other, with
patients drawn exclusively from the US in both cases. In
our study, the yearly incidence of hip and any fracture was
0.89 and 2.6%, respectively, without significant differences
between most DOPPS countries, after adjustment for
comorbidity and demographics. The yearly incidence of hip
fractures is markedly higher in HD patients than in the
general population across all 12 DOPPS countries. Indeed, in
the general population it ranges from 0.07 to 0.22% at a
similar mean age (around 60–65 years).26–28 Thus, our results
extend to the worldwide community of HD patients the
observation of a much higher risk of hip fracture in HD
versus non-uremic patients. In fact, as illustrated for the US
DOPPS and general populations (Figures 1 and 2), the hip
fracture incidence for HD patients of both sexes is similar to
the incidence observed among non-uremic subjects older by
10–20 years. This finding is not trivial in view of the more
than doubling of the RR of death associated with a hip
fracture in HD patients.3,29
The higher risk of hip fracture seen among HD patients
than among the general population has many possible
explanations. Our results demonstrating that an elevated
PTH level, independent of serum calcium and phosphorus,
increases the risk of fractures suggests that uremic osteo-
dystrophy may be one of the explanations. The higher risk
with longer time on dialysis may be related to both b2-
microglobulin amyloidosis and chronic uremic osteodystro-
phy. However, the higher risk of hip fracture associated with
HD likely reflects the higher risk of falling among HD
patients than among non-uremics, in line with a recent study
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on falls in HD patients.14 Both polymedication (among other
regimens with central nervous system active agents) and
comorbid conditions that reduce muscle mass and lessen the
ability to walk without assistance may be contributing
factors.
Another possible explanation is that hyperhomocysteine-
mia plays a role in the onset of fractures. Two recent large
prospective observational studies indeed found that a high
homocysteine level was an independent risk factor for hip or
osteoporotic (mainly hip/wrist) fractures in the US and the
Netherlands.12,30 That this relationship may be causal was
recently supported by a trial demonstrating a much lower
risk of hip fracture in hemiplegic patients randomized to
folate and vitamin B12 than in those taking a placebo.31 Post
hoc analyses of ongoing randomized, controlled trials of folic
acid supplementation in chronic kidney disease patients may
shed additional light on this topic.
Some limitations of the present study should be discussed.
First, the validity of the diagnoses of fractures was not (and
could not be) checked in this study. Fortunately, the
diagnosis of bone fracture is usually quite easy with widely
available skeletal X-rays, thus making a significant bias less
likely. Second, whereas hip fractures were distinguishable
from among all reported fracture-related events, other
fracture types were less well defined and consequently
analyzed collectively. Recognizably, the collective grouping
of ‘any type of fracture’ includes those having differential
degrees of structural and functional impairment. Should,
however, the pathophysiology of fractures be markedly
dependent on their location, the heterogeneity of ‘any
fractures’ would have reduced, rather than increased, the
power to detect risk factors. Finally, the medications taken by
each patient were recorded only at inclusion in the study and
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Figure 1 | Annual incidence of hip fracture, by age and sex.
General population incidence estimates from US Department of
Health and Human Services, Centers for Disease Control, National
Center for Health Statistics, National Hospital Discharge Survey, year
2000; DOPPS incidence estimates based on a period-prevalent
sample of patients and hospital admissions for hip fractures,
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Figure 2 | Associations between RR of new fracture and comorbid conditions. DOPPS II data (2002–2004), among all patients. Cox
models controlled for effects of facility clustering and all factors listed in Table 3 except the categorical counterparts of continuous measures
(e.g., categories of age/sex, years on ESRD, BMI, laboratory values).
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patient compliance with prescribed medication could not be
verified. This limitation should, however, have tended to
reduce (or blur) rather than increase the observed association
between some drugs and the prospective risk of fracture,
whereby an observed association is potentially understated
relative to the ‘true’ association if patients precisely adhered
to prescribed therapies. Thus, significant observations are
especially supported despite any bias introduced by non-
compliance, and weaker correlations might be demonstrably
significant in the presence of a perfectly compliant study
population.
In conclusion, our results suggest that more selective
prescription of psychoactive medications such as benzodia-
zepines, SSRI ADs, and narcotic medications, as well as more
effective treatment of severe hyperparathyroidism, are
promising strategies to reduce the burden of hip and other
bone fractures in HD patients.
MATERIALS AND METHODS
This study includes data gathered from 2002 to 2004 as part of
DOPPS II, an international, prospective, observational study of HD
practice patterns and their associated outcomes in 12 countries:
Australia, Belgium, Canada, France, Germany, Italy, Japan, New
Zealand, Spain, Sweden, the United Kingdom, and the US.
Nationally representative samples of dialysis facilities (n¼ 320)
were recruited in each country. Within each participating facility, a
prevalent cross-sectional patient sample was obtained by randomly
selecting 20–40 patients at the time the dialysis unit initiated data
collection, and totaled 9089 across the 320 facilities in DOPPS II.
Eligible patients were those aged 18 years or older and receiving
chronic, maintenance HD therapy within each selected dialysis unit.
Additionally, during the course of study participation, each facility
sequentially enrolled (up to) the first 15 patients aged 18 years or
older who had initiated chronic HD within the past 30 days
(n¼ 3693). Institutional review boards in each country approved
the study, and informed patient consent was obtained in accordance
with local requirements. Further details regarding DOPPS study
design, facility sampling, patient sampling, data collection, sample
size determinations, and data management have been reported
previously and are incorporated herein by reference.5,32
Medical record abstraction performed by facility staff was used to
obtain baseline data regarding demographic factors, comorbid
conditions, laboratory values, years since ESRD onset, and currently
prescribed medications upon patient entry into the study, and
similarly each patient’s medical record was also assessed for
occurrence of hip fracture, diagnosis of calciphylaxis, kidney
transplant, and parathyroidectomy at or before entry into the study.
Hospitalizations and outpatient visits (including fracture-related
visits) occurring during the study, along with diagnoses and
procedures relevant to the hospitalization or outpatient visit, were
reported chronologically for each patient. Such information was
generally made available prospectively by way of in-center patient
treatment records. Capturing both hospitalization events and
outpatient visits provided a reasonable expectation that the vast
majority of fracture-related events were recorded in this study. In the
DOPPS data, hip fractures were distinguishable from among all
reported fracture-related events, whereas fracture types other than
hip fracture were less well defined and consequently analyzed
collectively.
Primary analyses involving baseline patient characteristics
associated with a history of hip fracture were restricted to the
initial prevalent cross-sectional sample of 9089 patients. Statistical
modeling of time to new occurrence of hip fracture and any fracture
used the entire sample of 12 782 patients.
Statistical methods
Logistic regression was used to estimate associations between
baseline patient characteristics and history of hip fracture, as
indicated in the patients’ medical records. For these associations
multivariable models were used; these models accounted for facility
clustering effects using robust standard error estimates and were
adjusted for age, sex, race, BMI, years since ESRD onset, prior renal
transplant, prior parathyroidectomy, inability to walk without
assistance, residency in a nursing home, serum phosphorus,
albumin-corrected serum calcium, serum albumin, intact PTH,
serum bicarbonate, history of carpal tunnel syndrome or b2
microglobulin disorder, 13 summary comorbid conditions (coro-
nary artery disease, cerebrovascular disease, congestive heart failure,
other cardiovascular disease, cancer other than of the skin, diabetes
mellitus, gastrointestinal bleeding, hypertension, lung disease,
psychiatric disorder, neurologic disorder other than dementia,
peripheral vascular disease, and recurrent cellulitis or gangrene),
dementia, and country. Serum calcium was corrected for serum
levels of albumin by the following formula: Corrected calcium
(mg/dl)¼ total calcium (mg/dl)þ 0.8 (4–serum albumin (g/dl)).
The analyzed PTH data were based only on measurements from
facilities reporting use of the intact molecule PTH assay type
(approximately 90% of dialysis units). PTH values from facilities
reporting use of an assay type other than intact molecule assay were
not included in these analyses.
Cox proportional hazards regression models were used to assess
relationships between patient characteristics and time to first
reported occurrence of a new fracture event resulting in an inpatient
hospitalization or an outpatient visit for fracture care. All
Cox models accounted for facility clustering effects (using robust
standard estimates based on the sandwich estimator) and were
adjusted for having a history of hip fracture in addition to the
factors included in the logistic regression analyses described
above. Prospective associations between fracture events and a
variety of medication classes also were investigated. For these
analyses, time from enrollment to first reported occurrence of a new
fracture event initially was evaluated using Cox models adjusted
only for age, sex, country, and one medication class at a time.
Additional covariates for demographics, comorbidities, and labora-
tory measures subsequently were added to adjust for case mix
differences in these models, but still controlling for only one
medication per model.
All statistical analyses were performed with SAS software, version
9.1 (SAS Institute; Cary, NC, USA).
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